Takeda Strengthens Cancer Portfolio Through Innovent Partnership

Takeda has signed a license and collaboration agreement with Innovent Biologics and satisfied all the terms and transitioned the collaboration to the implementation phase.

The deal that was initially unveiled in October of 2025 enhances the global oncology strategy of Takeda and broadens its late-stage pipeline with two promising cancer therapies.

The agreement grants Takeda global rights in an exclusion of Greater China in IBI363 and IBI343, which are late-stage research drugs against the hard-to-treat cancers. IBI363 is in clinical trials in non-solid tumor lung cancer and colorectal cancer and demonstrates potential in a number of other solid tumors. IBI343 is expected to be used in gastric and pancreatic cancer, which is an untapped medical field with increasing new treatment requirements.

Also Read: Takeda's Adzynma Under FDA Scrutiny Following Pediatric Fatality

Takeda shall head the international co-development and co-commercialization of IBI363 in the US. It has the exclusivity in every region except the U.S and Greater China, and in the whole world, it has manufacturing rights barred to Greater China, with the U.S supply sharing with Innovent. In the case of IBI343, Takeda will have the entire development, manufacturing, and commercial rights beyond Greater China and will establish production capacity in the United States.

“Our collaboration with Innovent reflects the power of partnerships in oncology,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “By combining innovative science with global development and commercialization expertise, we can advance more options for patients with the potential to address critical treatment gaps. This agreement reflects our deep commitment to developing medicines that enhance and extend the lives of people living with cancer.”

This agreement also includes an exclusive option for Takeda to license global rights to IBI3001, which is an early-stage candidate, outside Greater China. Takeda will make payments of up to 1.2 billion dollars at one point, including a US$100 million equity investment, prior to the end of Takeda’s fiscal year, ending March 31, 2026.